AADI - Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

• Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa.
• Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients.
• Further expansion of ABI-009 can be achieved with targeting other cancer subpopulations that have the mTOR pathway.
• Aadi Bioscience had $161.4 million in cash and cash equivalents as of September 30, 2021; enough cash to fund operations into 2024.

For further details see: